These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 35234288)

  • 1. Plasma α-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease.
    Ren J; Pan C; Wang Y; Xue C; Lin H; Xu J; Wang H; Zhang W; Xu P; Chen Y; Liu W
    J Neurochem; 2022 Jun; 161(6):506-515. PubMed ID: 35234288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes.
    Li Q; Li Z; Han X; Shen X; Wang F; Bai L; Li Z; Zhang R; Wang Y; Zhu X
    Front Neurosci; 2022; 16():805953. PubMed ID: 35250451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting.
    Youssef P; Hughes L; Kim WS; Halliday GM; Lewis SJG; Cooper A; Dzamko N
    Sci Rep; 2023 Mar; 13(1):5217. PubMed ID: 36997567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson's disease: a prospective cohort study.
    Lin J; Ou R; Li C; Hou Y; Zhang L; Wei Q; Pang D; Liu K; Jiang Q; Yang T; Xiao Y; Zhao B; Chen X; Song W; Yang J; Wu Y; Shang H
    BMC Med; 2023 Nov; 21(1):420. PubMed ID: 37932720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease.
    Blommer J; Pitcher T; Mustapic M; Eren E; Yao PJ; Vreones MP; Pucha KA; Dalrymple-Alford J; Shoorangiz R; Meissner WG; Anderson T; Kapogiannis D
    Brain; 2023 Jan; 146(1):195-208. PubMed ID: 35833836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Combined Panel of Salivary Biomarkers in de novo Parkinson's Disease.
    De Bartolo MI; Vivacqua G; Belvisi D; Mancinelli R; Fabbrini A; Manzo N; Costanzo M; Leodori G; Conte A; Fabbrini G; Morini S; Berardelli A
    Ann Neurol; 2023 Mar; 93(3):446-459. PubMed ID: 36385395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
    Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
    Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution and Predictive Role of Plasma Alzheimer's Disease-related Pathological Biomarkers in Parkinson's Disease.
    Lin J; Ou R; Li C; Hou Y; Zhang L; Wei Q; Liu K; Jiang Q; Yang T; Xiao Y; Pang D; Zhao B; Chen X; Yang J; Shang H
    J Gerontol A Biol Sci Med Sci; 2023 Dec; 78(12):2203-2213. PubMed ID: 37560912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
    Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.
    Nabizadeh F; Pirahesh K; Ramezannezhad E
    Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma total tau predicts executive dysfunction in Parkinson's disease.
    Lin WT; Shaw JS; Cheng FY; Chen PH
    Acta Neurol Scand; 2022 Jan; 145(1):30-37. PubMed ID: 34398474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson's disease development and progression.
    Niu M; Li Y; Li G; Zhou L; Luo N; Yao M; Kang W; Liu J
    Eur J Neurol; 2020 Jun; 27(6):967-974. PubMed ID: 32150777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.
    Oosterveld LP; Verberk IMW; Majbour NK; El-Agnaf OM; Weinstein HC; Berendse HW; Teunissen CE; van de Berg WDJ
    Mov Disord; 2020 Feb; 35(2):288-295. PubMed ID: 31737952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease.
    Pagonabarraga J; Pérez-González R; Bejr-Kasem H; Marín-Lahoz J; Horta-Barba A; Martinez-Horta S; Aracil-Bolaños I; Sampedro F; Campolongo A; Rivas E; Puig-Davi A; Ruiz-Barrios I; Pérez-Pérez J; Pascual-Sedano B; Kulisevsky J
    Parkinsonism Relat Disord; 2022 Dec; 105():132-138. PubMed ID: 35752549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
    J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.
    Nabizadeh F; Pirahesh K; Valizadeh P
    J Neurol; 2022 Sep; 269(9):4836-4845. PubMed ID: 35426534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower Plasma α-Synuclein Levels are Associated with Cognitive Impairment in Parkinson's Disease.
    Song Z; Shen J; Liu Y; Du X; Wu Y; Liu X; Zhang J
    Clin Lab; 2021 May; 67(5):. PubMed ID: 33978361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease.
    von Euler Chelpin M; Söderberg L; Fälting J; Möller C; Giorgetti M; Constantinescu R; Blennow K; Zetterberg H; Höglund K
    J Parkinsons Dis; 2020; 10(4):1429-1442. PubMed ID: 33016895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.